Dr. Reddy's Laboratories (BSE:500124) - Stock Price, News & Analysis

500124 Stock Overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

About the company

500124 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	5/6

Rewards

Price-To-Earnings ratio (19x) is below the Indian market (31.3x)

Earnings grew by 43.6% over the past year

Pays a reliable dividend of 0.67%

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for 500124 from our risk checks.

Dr. Reddy's Laboratories Limited Competitors

Mankind Pharma

NSEI:MANKIND

₹960.7b

Zydus Lifesciences

NSEI:ZYDUSLIFE

₹939.3b

Cipla

NSEI:CIPLA

₹1.1t

Torrent Pharmaceuticals

BSE:500420

₹908.7b

Price History & Performance

Summary of all time highs, changes and price drops for Dr. Reddy's Laboratories
Historical stock prices
Current Share Price	₹5,951.20
52 Week High	₹6,505.50
52 Week Low	₹4,383.40
Beta	0.34
1 Month Change	-4.04%
3 Month Change	1.66%
1 Year Change	22.85%
3 Year Change	18.00%
5 Year Change	102.92%
Change since IPO	34,865.87%

Recent updates

Shareholder Returns

	500124	IN Pharmaceuticals	IN Market
7D	-1.7%	-0.1%	1.8%
1Y	22.9%	55.9%	46.4%

Return vs Industry: 500124 underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.

Return vs Market: 500124 underperformed the Indian Market which returned 46.1% over the past year.

Price Volatility

Is 500124's price volatile compared to industry and market?
500124 volatility
500124 Average Weekly Movement	2.9%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.9%
10% most volatile stocks in IN Market	10.1%
10% least volatile stocks in IN Market	4.2%

Stable Share Price: 500124 has not had significant price volatility in the past 3 months.

Volatility Over Time: 500124's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1984	25,863	Erez Israeli	www.drreddys.com

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.

Dr. Reddy's Laboratories Limited Fundamentals Summary

How do Dr. Reddy's Laboratories's earnings and revenue compare to its market cap?
500124 fundamental statistics
Market cap	₹991.01b
Earnings (TTM)	₹52.21b
Revenue (TTM)	₹271.30b

19.0x

P/E Ratio

3.7x

P/S Ratio

Is 500124 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
500124 income statement (TTM)
Revenue	₹271.30b
Cost of Revenue	₹113.18b
Gross Profit	₹158.12b
Other Expenses	₹105.92b
Earnings	₹52.21b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)	313.51
Gross Margin	58.28%
Net Profit Margin	19.24%
Debt/Equity Ratio	6.0%

How did 500124 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

13%

Payout Ratio

500124 Stock Overview

Rewards

Risk Analysis

Dr. Reddy's Laboratories Limited Competitors

NSEI:MANKIND

₹960.7b

NSEI:ZYDUSLIFE

₹939.3b

NSEI:CIPLA

₹1.1t

BSE:500420

₹908.7b

Price History & Performance

Recent News & Updates

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Price target increased by 7.7% to ₹5,388

Dr. Reddy's Laboratories Limited Announces Management Changes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Upcoming dividend of ₹40.00 per share at 0.8% yield

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Consensus EPS estimates increase by 17%

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Upcoming dividend of ₹30.00 per share

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).